Key result
Trial tests Ayurvedic add-on therapy vs standard care for post-MI cardiac remodelling and symptoms.
Why the study?
Despite reperfusion and standard pharmacological therapy, post-MI patients remain at risk for left ventricular dysfunction, adverse cardiac remodelling, recurrent ischemic symptoms, and reduced quality of life. Evidence regarding the combined efficacy of Nagabala-Arjunadi Yoga and Arogyavardhini Rasa in post-MI management remains limited.
Does the addition of Nagabala-Arjunadi Yoga and Arogyavardhini Rasa to standard care improve left ventricular function, cardiac remodelling parameters, NT-proBNP levels, and ischemic symptoms in post-myocardial infarction patients?
RCT (n=106)
Open-label
Computer-generated randomization (1:1 parallel group)
No
Does the addition of Nagabala-Arjunadi Yoga and Arogyavardhini Rasa to standard care improve left ventricular function, cardiac remodelling parameters, NT-proBNP levels, and ischemic symptoms in post-myocardial infarction patients?
This study protocol outlines a randomized, open-label clinical trial to evaluate whether adding the Ayurvedic formulations Nagabala-Arjunadi Yoga and Arogyavardhini Rasa to standard post-MI care improves echocardiographic ventricular remodeling parameters, NT-proBNP levels, and clinical symptoms over 12 weeks.
Answers are grounded in this paper and cite their sources.
Protocol for RCT of Ayurvedic add-on post-MI; leaves open efficacy and should not change practice.
Background: Myocardial infarction (MI) is a major cause of cardiovascular morbidity and mortality. Despite advances in reperfusion and standard pharmacological management, patients may develop left ventricular dysfunction, adverse cardiac remodelling, recurrent ischemic symptoms, reduced functional capacity, and impaired quality of life. Nagabala-Arjunadi Yoga has shown beneficial effects on cardiac symptoms, left ventricular ejection fraction (LVEF), and quality of life in previous study. Arogyavardhini Rasa, with its Hridya (Cardioprotective), Lekhana (Scraping action), and Medohara (Hypolipidemic) properties, may provide additional cardiovascular benefits. However, evidence regarding their combined efficacy in post-MI management remains limited. Objectives were to evaluate the efficacy of Nagabala-Arjunadi Yoga and Arogyavardhini Rasa as add-on to standard care in post-MI patients. Methods: This prospective, open-label, randomized, standard-controlled clinical trial will enrol 106 post-MI patients. Participants will be allocated to receive either Nagabala-Arjunadi Yoga and Arogyavardhini Rasa alongside standard care or standard care alone for 12 weeks. Primary outcomes will include changes in LVEF, left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), N-terminal pro-B-type natriuretic peptide (NT-proBNP), angina severity, fatigue, dyspnoea, and functional capacity. Health-related quality of life (HRQoL) will be assessed using the MacNew questionnaire as a secondary outcome. Assessments will be performed at baseline and post-treatment. Appropriate parametric and non-parametric statistical tests will be applied, with p<0.05 considered statistically significant. Conclusions: The study will evaluate whether these Ayurvedic formulations, as add-on to standard care, improve cardiac function, remodelling parameters, NT-proBNP levels, ischemic symptoms, functional capacity, and quality of life in post-MI patients. Trial Registration: The trial is registered with Clinical Trial Registry of India (CTRI). CTRI/2026/07/114947.
No takes yet. Share an insight, caveat, or question.
Barvadia et al. (2026) conducted an RCT in Post-myocardial infarction (n=106). Nagabala-Arjunadi Yoga and Arogyavardhini Rasa add-on to standard care vs. Standard care alone (ACE inhibitors, dual antiplatelet therapy, beta-blockers, statins) was evaluated on Changes in LVEF, LVEDV, LVESV, NT-proBNP, angina severity (CCS scale), fatigue, dyspnoea, and functional capacity (NYHA class). Nagabala-Arjunadi Yoga and Arogyavardhini Rasa added to standard care will be evaluated in 106 post-MI patients over 12 weeks in this ongoing clinical trial protocol with no results yet reported.
Synapse has enriched 10 related papers. Consider them for comparative context: